[3] Weight loss typically follows a predictable pattern: Initial phase (0-3 months): Gradual dose escalation with modest weight reduction as appetite suppression begins Active loss phase (3-12 months): Most significant weight reduction occurs during this period Plateau phase (12+ months): Weight stabilises
& Matafome, P
At the bare minimum, significant, asymmetric upside exists in the immediate short term in the following forms: Cheaper subscriber acquisition stemming from the hype and a leading DTC brand name ( marketing expenses as a % of revenue dropped 5% to 46% through strong retention, brand recognition, and lower-cost acquisition channels )
It targets the brains appetite centers, reducing the overall desire to eat
Authors perspective and future directions Current evidence supports SGLT2 inhibitors as a core component of contemporary heart failure management because of their consistent reductions in HF hospitalization and cardiovascular death across a broad range of patient populations [8,9,10,11,12,13, 45, 49]